These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 31061402)
1. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. Quadeer AA; Louie RHY; McKay MR Nat Commun; 2019 May; 10(1):2073. PubMed ID: 31061402 [TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875 [TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098 [TBL] [Abstract][Full Text] [Related]
5. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340 [TBL] [Abstract][Full Text] [Related]
6. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. Keck ZY; Angus AG; Wang W; Lau P; Wang Y; Gatherer D; Patel AH; Foung SK PLoS Pathog; 2014 Aug; 10(8):e1004297. PubMed ID: 25122476 [TBL] [Abstract][Full Text] [Related]
7. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563 [TBL] [Abstract][Full Text] [Related]
8. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964 [TBL] [Abstract][Full Text] [Related]
9. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. El Abd YS; Tabll AA; El Din NG; Hosny Ael-D; Moustafa RI; El-Shenawy R; Atef K; El-Awady MK Virol J; 2011 Aug; 8():391. PubMed ID: 21819575 [TBL] [Abstract][Full Text] [Related]
10. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus. Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828 [TBL] [Abstract][Full Text] [Related]
11. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595 [TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021 [TBL] [Abstract][Full Text] [Related]
13. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE J Virol; 2018 May; 92(9):. PubMed ID: 29467319 [TBL] [Abstract][Full Text] [Related]
14. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219 [TBL] [Abstract][Full Text] [Related]
15. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044 [TBL] [Abstract][Full Text] [Related]
16. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001 [TBL] [Abstract][Full Text] [Related]
17. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422 [TBL] [Abstract][Full Text] [Related]
18. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681 [TBL] [Abstract][Full Text] [Related]
19. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602 [TBL] [Abstract][Full Text] [Related]
20. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. Keck ZY; Saha A; Xia J; Wang Y; Lau P; Krey T; Rey FA; Foung SK J Virol; 2011 Oct; 85(20):10451-63. PubMed ID: 21813602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]